{"id":"ivermectin-1-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL6067487","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin is a macrocyclic lactone that selectively activates glutamate-gated chloride ion channels in invertebrate nervous and muscular systems, leading to hyperpolarization, paralysis, and death of susceptible parasites and arthropods. In topical cream formulation, it penetrates the skin to reach mites and other ectoparasites in the dermis and epidermis. The mechanism is highly selective for invertebrate channels with minimal effects on mammalian physiology.","oneSentence":"Ivermectin binds to glutamate-gated chloride channels in parasites and arthropods, causing paralysis and death of the organisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:33.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rosacea (topical treatment of inflammatory lesions)"},{"name":"Scabies (topical treatment)"}]},"trialDetails":[{"nctId":"NCT04332068","phase":"PHASE2","title":"Ivermectin Safety in Small Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-11-18","conditions":"Scabies","enrollment":240},{"nctId":"NCT06896929","phase":"PHASE2","title":"Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies","status":"NOT_YET_RECRUITING","sponsor":"Children Hospital and Institute of Child Health, Lahore","startDate":"2025-05-01","conditions":"Scabies","enrollment":90},{"nctId":"NCT06033352","phase":"PHASE2","title":"Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-12","conditions":"Rosacea","enrollment":22},{"nctId":"NCT06557603","phase":"PHASE1","title":"Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-03-06","conditions":"Rosacea","enrollment":44},{"nctId":"NCT05819983","phase":"PHASE4","title":"Ivermectin/ Permethrin for Scabies","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2023-01-25","conditions":"Scabies","enrollment":60},{"nctId":"NCT05362513","phase":"PHASE1","title":"Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2021-06-01","conditions":"Scabies","enrollment":100},{"nctId":"NCT05213585","phase":"PHASE1","title":"Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%","status":"UNKNOWN","sponsor":"Helm Vision Group","startDate":"2021-08-24","conditions":"The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves","enrollment":20},{"nctId":"NCT03075891","phase":"PHASE4","title":"Oracea Soolantra Association in Participants With Severe Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-07-05","conditions":"Rosacea","enrollment":273},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT03177993","phase":"NA","title":"Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-07-13","conditions":"Lymphatic Filariases, Scabies, Impetigo","enrollment":4773},{"nctId":"NCT04106726","phase":"PHASE3","title":"Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea","status":"COMPLETED","sponsor":"Zydus Worldwide DMCC","startDate":"2019-10-17","conditions":"Facial Rosacea","enrollment":525},{"nctId":"NCT02840461","phase":"PHASE3","title":"Clinical Endpoint Study of Ivermectin 1% Cream","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-06","conditions":"Moderate to Severe Papulopustular Rosacea","enrollment":630},{"nctId":"NCT01493947","phase":"PHASE3","title":"CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-04","conditions":"Papulopustular Rosacea","enrollment":962},{"nctId":"NCT02036229","phase":"PHASE3","title":"Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2014-02","conditions":"Demodicidosis, Rosacea","enrollment":50},{"nctId":"NCT00988533","phase":"PHASE1","title":"A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2009-09","conditions":"Head Lice","enrollment":30},{"nctId":"NCT01068158","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2010-03","conditions":"Head Lice","enrollment":371},{"nctId":"NCT00994422","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2009-10","conditions":"Head Lice","enrollment":264},{"nctId":"NCT01066585","phase":"PHASE3","title":"A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","startDate":"2010-03","conditions":"Head Lice","enrollment":410}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Soolantra"],"phase":"marketed","status":"active","brandName":"Ivermectin 1% cream","genericName":"Ivermectin 1% cream","companyName":"Insel Gruppe AG, University Hospital Bern","companyId":"insel-gruppe-ag-university-hospital-bern","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin 1% cream is used to treat conditions such as head lice, scabies, and rosacea. It works by modulating the glutamate-gated chloride channel, a specific molecular target.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-19T00:00:00.000Z","mah":"GALDERMA LABS LP","brand_name_local":"SOOLANTRA","application_number":"NDA206255"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}